Durvalumab
Locally Advanced NSCLC: Durvalumab and the PACIFIC Trial
3:07
The Use of Durvalumab in Locally Advanced NSCLC
1:46
Durvalumab bei der Therapie vom NSCLC im Stadium III | Strahlentherapie Prof. Hilke Vorwerk
1:24
Durvalumab: the new standard of care for NSCLC?
2:31
Perioperative Durvalumab in Bladder Cancer | NEJM
1:44
Real-world outcomes of durvalumab ± tremelimumab in uHCC
2:43
FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer
4:15
Safety Profile of Durvalumab in Locally Advanced NSCLC
3:48
POSEIDON: durvalumab +/- tremelimumab + chemo in 1L mNSCLC
2:15
Durvalumab (Imfinzi): How It Works, Benefits, and Side Effects Explained
1:22
Evaluating durvalumab and chemotherapy for MIBC in the NIAGARA trial
0:58
An Expert’s Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung Cancers
2:37
TOURMALINE: durvalumab and gemcitabine-based chemotherapy in BTC
1:17
The impact of durvalumab on the SCLC treatment landscape
7:18
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma
2:56
Durvalumab after chemoradiotherapy improves overall survival in lung cancer patients
1:28
Durvalumab / Imfinzi (NIAGRA Trial) Defies Odds in MIBC Survival Benefits Beyond Complete Response
7:47
Combination tremelimumab and durvalumab in HCC
2:49
Durvalumab - Imfinzi - All You Need to Know in 2 Minutes.
5:11
NIAGARA: Perioperative Durvalumab Shows Overall Survival Benefit in Muscle-Invasive Bladder Cancer